# Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors

Source: https://onco.cc/trials/nct07095868/  
OnCo record `nct07095868` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Everest Medicines (Beijing) Co., Ltd., now recruiting.

## Summary

Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors is a phase 1/2 interventional study registered as NCT07095868 by Everest Medicines (Beijing) Co., Ltd., with 94 participants planned, started 2025-11-17 and due to reach its primary completion in 2029-11. Interventions recorded: EVM14 and Pembrolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07095868
- Phase: 1/2
- Setting: A Phase I/IIa Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Solid Tumors
- Sponsor: Everest Medicines (Beijing) Co., Ltd.
- Enrolled: 94

## Sources

- ClinicalTrials.gov NCT07095868: https://clinicaltrials.gov/study/NCT07095868

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [EVM14](https://onco.cc/drugs/evm14/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct07095868.json